Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYNK-101 with Trastuzumab and Pembrolizumab in HER2+ Gastric/GEJ Cancer
NCT05207722Phase 2Terminated
- Sponsor
- Celularity Inc.
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of CYNK-101 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Celularity Inc. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Apr 2022; status: terminated.
02
Drugs
CYNK-101
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05207722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207722.